Rodriguez-Mogeda C, van Ansenwoude C, van der Molen L, Strijbis E, Mebius R, de Vries H
J Neuroinflammation. 2024; 21(1):48.
PMID: 38350967
PMC: 10865604.
DOI: 10.1186/s12974-024-03040-8.
Zhang Y, Zhang H, Chen H, Lv P, Su J, Chen Y
J Neuroinflammation. 2023; 20(1):216.
PMID: 37752509
PMC: 10523659.
DOI: 10.1186/s12974-023-02891-x.
Birmpili D, Charmarke Askar I, Bigaut K, Bagnard D
Int J Mol Sci. 2022; 23(19).
PMID: 36232832
PMC: 9570245.
DOI: 10.3390/ijms231911532.
Fabre M, Mateo L, Lamaa D, Baillif S, Pages G, Demange L
Molecules. 2022; 27(16).
PMID: 36014339
PMC: 9414333.
DOI: 10.3390/molecules27165089.
Sadeghi Hassanabadi N, Broux B, Marinovic S, Gotthardt D
Front Immunol. 2022; 13:909275.
PMID: 35784374
PMC: 9247827.
DOI: 10.3389/fimmu.2022.909275.
Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.
Kasindi A, Fuchs D, Koronyo Y, Rentsendorj A, Black K, Koronyo-Hamaoui M
Cells. 2022; 11(9).
PMID: 35563884
PMC: 9099707.
DOI: 10.3390/cells11091578.
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.
Yong H, Yong V
Nat Rev Neurol. 2021; 18(1):40-55.
PMID: 34732831
DOI: 10.1038/s41582-021-00581-x.
Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review.
Rojas J, Patrucco L, Cristiano E
Degener Neurol Neuromuscul Dis. 2020; 4:103-109.
PMID: 32669904
PMC: 7337150.
DOI: 10.2147/DNND.S46557.
Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.
De Kleijn K, Martens G
Int J Mol Sci. 2020; 21(12).
PMID: 32545828
PMC: 7352301.
DOI: 10.3390/ijms21124229.
The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis.
Monaghan K, Wan E
Cells. 2020; 9(3).
PMID: 32143326
PMC: 7140439.
DOI: 10.3390/cells9030611.
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.
Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S
Ther Adv Neurol Disord. 2019; 12:1756286419836571.
PMID: 30967901
PMC: 6444778.
DOI: 10.1177/1756286419836571.
The benefits of neuroinflammation for the repair of the injured central nervous system.
Yong H, Rawji K, Ghorbani S, Xue M, Yong V
Cell Mol Immunol. 2019; 16(6):540-546.
PMID: 30874626
PMC: 6804643.
DOI: 10.1038/s41423-019-0223-3.
Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis.
Chen Y, Podojil J, Kunjamma R, Jones J, Weiner M, Lin W
Brain. 2019; 142(2):344-361.
PMID: 30657878
PMC: 6351782.
DOI: 10.1093/brain/awy322.
To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis.
De Laere M, Berneman Z, Cools N
J Neuropathol Exp Neurol. 2018; 77(3):178-192.
PMID: 29342287
PMC: 5901086.
DOI: 10.1093/jnen/nlx114.
Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression.
White M, Webster G, Leonard F, La Flamme A
Sci Rep. 2018; 8(1):259.
PMID: 29321652
PMC: 5762891.
DOI: 10.1038/s41598-017-18543-z.
The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.
Tremlett H, Waubant E
Neurotherapeutics. 2017; 15(1):102-108.
PMID: 28940049
PMC: 5794692.
DOI: 10.1007/s13311-017-0574-3.
Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.
Suthiphosuwan S, Kim D, Bharatha A, Oh J
Curr Treat Options Neurol. 2017; 19(5):18.
PMID: 28417345
DOI: 10.1007/s11940-017-0453-6.
MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.
Brown R, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L
Neurology. 2016; 87(9):905-11.
PMID: 27473139
PMC: 5035157.
DOI: 10.1212/WNL.0000000000003043.
Dendritic cells as therapeutic targets in neuroinflammation.
Luessi F, Zipp F, Witsch E
Cell Mol Life Sci. 2016; 73(13):2425-50.
PMID: 26970979
PMC: 11108452.
DOI: 10.1007/s00018-016-2170-9.
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].
Klotz L, Berthele A, Bruck W, Chan A, Flachenecker P, Gold R
Nervenarzt. 2016; 87(6):645-59.
PMID: 26927677
DOI: 10.1007/s00115-016-0077-1.